Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,906.50GBp
14 Dec 2017
Change (% chg)

-18.50 (-0.38%)
Prev Close
4,925.00
Open
4,911.00
Day's High
4,945.00
Day's Low
4,905.00
Volume
267,030
Avg. Vol
2,441,427
52-wk High
5,585.07
52-wk Low
4,136.50

Latest Key Developments (Source: Significant Developments)

Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Iovance Biotherapeutics Inc ::IOVANCE BIOTHERAPEUTICS ANNOUNCES MANUFACTURING DECISION, PROVIDES CLINICAL UPDATES AND HIGHLIGHTS PIPELINE EXPANSION AT ANALYST DAY 2017.IOVANCE BIOTHERAPEUTICS - SELECTED ITS GEN 2 MANUFACTURING PROCESS FOR ALL THREE PHASE 2 TRIALS, ALL FUTURE TIL CLINICAL DEVELOPMENT.IOVANCE - PROTOCOLS FOR 3 EXISTING STUDIES HAVE BEEN AMENDED TO ALLOW ENROLLMENT OF NEW PATIENTS WITH TIL MANUFACTURED WITH GEN 2 PROCESS.IOVANCE - COHORT 1 OF C-144-01 MELANOMA STUDY WILL BE CLOSED AND NEW PATIENTS WILL BE ENROLLED IN COHORT 2.IOVANCE - PHASE 2 STUDY IN PD-1 AND PD-L1 NAÏVE NSCLC PATIENTS WILL INITIATE IN H1 2018.IOVANCE - MD ANDERSON CANCER CENTER TO INITIATE 2 BASKET STUDIES IN SARCOMA & PLATINUM RESISTANT OVARIAN CANCER.IOVANCE - CO RETAINS RIGHTS TO MDA PRECLINICAL RESEARCH IN EXPANDING UNDERSTANDING OF TIL, RELATED INTELLECTUAL PROPERTY.  Full Article

Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Pieris Pharmaceuticals Inc ::PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402.PIERIS PHARMACEUTICAL - THE PHASE 1 STUDY IS BEING DEVELOPED AS PART OF PIERIS' STRATEGIC ALLIANCE WITH ASTRAZENECA.PIERIS PHARMACEUTICALS - DOSING FIRST SUBJECT IN TRIAL FOR PRS-060/AZD1402 BY YEAR END.  Full Article

Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS COMMENCES PIVOTAL STUDY FOR FULVESTRANT.EAGLE PHARMACEUTICALS- ANTICIPATES COMPLETION OF FULVESTRANT STUDY WITHIN TWELVE MONTHS, AND AN EXPECTED NDA FILING IN Q4 OF 2018.  Full Article

G1 Therapeutics And AstraZeneca Enter Clinical Trial Collaboration In Non-Small Cell Lung Cancer
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - G1 Therapeutics Inc ::G1 THERAPEUTICS AND ASTRAZENECA ENTER CLINICAL TRIAL COLLABORATION IN NON-SMALL CELL LUNG CANCER.- ‍FINANCIAL TERMS OF NON-EXCLUSIVE COLLABORATION HAVE NOT BEEN DISCLOSED​.G1 THERAPEUTICS - ‍COLLABORATION TO EVALUATE ASTRAZENECA'S EGFR TYROSINE KINASE INHIBITOR TAGRISSO IN COMBINATION WITH G1'S ORAL CDK4/6 INHIBITOR G1T38​.G1 THERAPEUTICS SAYS IT WILL SPONSOR AND CONDUCT A PHASE 1B/2 STUDY IN COLLABORATION WITH ASTRAZENECA IN PATIENTS WITH NSCLC​.SAYS ‍PLANS TO INITIATE TRIAL IN Q1 OF 2018​.  Full Article

Astrazeneca Plc says EMA accepts Tagrisso submission for 1st-line nsclc
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - ASTRAZENECA PLC ::‍EMA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLC​.‍EUROPEAN MEDICINES AGENCY ACCEPTS REGULATORY SUBMISSION FOR TAGRISSO IN 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER​.  Full Article

Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca‍​
Friday, 17 Nov 2017 

Nov 17 (Reuters) - ALMIRALL SA ::ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA‍​.  Full Article

Astrazeneca says U.S. FDA approved fasenra (benralizumab) for severe eosinophilic asthma
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Astrazeneca Plc :Astrazeneca - co, Medimmune, announced that U.S. FDA approved fasenra (benralizumab) for severe eosinophilic asthma.Astrazeneca - FDA approval based on phase III programme showing up to 51 pct reduction in asthma exacerbations & 75 pct reduction in daily oral steroid use‍​.  Full Article

Astrazeneca says EU approves new indication for Faslodex in combination with palbociclib
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Astrazeneca Plc :FASLODEX (FULVESTRANT) RECEIVES EU APPROVAL FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB1.  Full Article

Astrazeneca says Benralizumab receives Positive EU CHMP opinion
Friday, 10 Nov 2017 

Nov 10 (Reuters) - ASTRAZENECA PLC ::BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMA.‍ANNOUNCED THAT CHMP OF EUROPEAN MEDICINES AGENCY HAS ADOPTED POSITIVE OPINION, RECOMMENDING MARKETING AUTHORISATION OF BENRALIZUMAB​.  Full Article

AstraZeneca CEO committed to dividend
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - AstraZeneca CEO Pascal Soriot says::* committed to dividend "today, tomorrow and day after".  Full Article

Bumper crop of new drugs fails to lift big pharma R&D returns

LONDON, Dec 14 It is shaping up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down.